Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
Source: ClinicalTrials.gov NCT02582658 ↗Summary
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) |
84.8 | — |
| SECONDARY Percentage of Participants With Virological Response at End of Treatment (EoTR) |
94.5 | — |
| SECONDARY Percentage of Participants With On-treatment Virologic Failure (Breakthrough) |
1.2 | — |
| SECONDARY Percentage of Participants Achieving SVR12 (Core Population Sufficient Follow-up) |
95.9 | — |
| SECONDARY Percentage of Participants With Post-treatment Relapse |
0.0 | — |
Eligibility Criteria
Inclusion Criteria
Treatment-naïve or -experienced adult male or female patients with confirmed chronic hepatitis C, genotype (GT)1 or GT4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± Ribavirin (RBV) according to standard of care and in line with the current local label
If RBV is co-administered with the ABBVIE REGIMEN, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)
Patients must voluntarily sign and date a patient authorization to use and disclose his/her anonymized health data prior to inclusion into the study
Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial
Exclusion Criteria
none
Data sourced from ClinicalTrials.gov (NCT02582658). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.